Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 16/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14893494 | 1.00 | TRPV3 (0.53) | TRPV3SLC6A3SLC6A4SLC6A2KCNH2 | |
| SCHEMBL14893503 | 1.00 | TRPV3 (0.53) | TRPV3SLC6A3SLC6A4SLC6A2KCNH2 | |
| SCHEMBL14894140 | 1.00 | TRPV3 (0.53) | TRPV3SLC6A3SLC6A4SLC6A2KCNH2 | |
| SCHEMBL14893495 | 1.00 | TRPV3 (0.53) | TRPV3SLC6A3SLC6A4SLC6A2KCNH2 | |
| SCHEMBL14893845 | 0.86 | TRPV3 (0.73) | TRPV3SLC6A3SLC6A4SLC6A2KCNH2 | |
| SCHEMBL14893614 | 0.86 | TRPV3 (0.73) | TRPV3SLC6A3SLC6A4SLC6A2KCNH2 | |
| SCHEMBL14893749 | 0.86 | TRPV3 (0.73) | TRPV3SLC6A3SLC6A4SLC6A2KCNH2 | |
| SCHEMBL14893615 | 0.86 | TRPV3 (0.73) | TRPV3SLC6A3SLC6A4SLC6A2KCNH2 | |
| SCHEMBL14893843 | 0.86 | TRPV3 (0.73) | TRPV3SLC6A3SLC6A4SLC6A2KCNH2 | |
| SCHEMBL14893847 | 0.86 | TRPV3 (0.73) | TRPV3SLC6A3SLC6A4SLC6A2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2771322-A2 | NOVEL TRPV3 MODULATORS | AbbVie Inc. (US) | 2014-09-03 | — | — | EP | claimed |
| US-8772499-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2014-07-08 | — | — | US | claimed |
| US-20140080803-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2014-03-20 | — | — | US | claimed |
| WO-2013062964-A2 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-05-02 | — | — | WO | claimed |
| EP-2771322-A2 | NOVEL TRPV3 MODULATORS | AbbVie Inc. (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8772499-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772500-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20140080803-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20130131036-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2013062964-A2 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013062966-A2 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131036-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | TRPV3 1/4885SLC6A3 553/4885SLC6A4 467/4885 |
| US-20140080803-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | TRPV3 1/4885SLC6A3 747/4885SLC6A4 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.